Dr. James Berenson discusses the importance of using maintenance therapies with limited short- or long-term side effects, in particular avoiding therapies that have long-term toxicity. Dr. Berenson expresses his excitement that within the next few years there is hope for curative therapy by using drugs that are “piggybacked” and delivered at a “thousand folds” higher rate to hit only the myeloma cells, versus the entire body.